HomeCompareCBAY vs VIG

CBAY vs VIG: Dividend Comparison 2026

CBAY yields 6.16% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIG wins by $2.3K in total portfolio value· pulled ahead in Year 3
10 years
CBAY
CBAY
● Live price
6.16%
Share price
$32.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.0K
Annual income
$911.52
Full CBAY calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — CBAY vs VIG

📍 VIG pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBAYVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBAY + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBAY pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBAY
Annual income on $10K today (after 15% tax)
$523.40/yr
After 10yr DRIP, annual income (after tax)
$774.79/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, CBAY beats the other by $622.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBAY + VIG for your $10,000?

CBAY: 50%VIG: 50%
100% VIG50/50100% CBAY
Portfolio after 10yr
$31.2K
Annual income
$545.34/yr
Blended yield
1.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CBAY right now

CBAY
Analyst Ratings
11
Buy
12
Hold
Consensus: Hold
Altman Z
12.9
Piotroski
4/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBAY buys
0
VIG buys
0
No recent congressional trades found for CBAY or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBAYVIG
Forward yield6.16%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$30.0K$32.4K
Annual income after 10y$911.52$179.15
Total dividends collected$7.7K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CBAY vs VIG ($10,000, DRIP)

YearCBAY PortfolioCBAY Income/yrVIG PortfolioVIG Income/yrGap
1$11,316$615.76$11,304$163.92+$12.00CBAY
2$12,759$651.20$12,759$166.33$0.00VIG
3← crossover$14,338$686.22$14,382$168.52$44.00VIG
4$16,063$720.72$16,192$170.52$129.00VIG
5$17,942$754.57$18,210$172.34$268.00VIG
6$19,985$787.70$20,460$173.98$475.00VIG
7$22,204$820.02$22,968$175.48$764.00VIG
8$24,610$851.47$25,763$176.83$1.2KVIG
9$27,215$881.98$28,878$178.05$1.7KVIG
10$30,031$911.52$32,350$179.15$2.3KVIG

CBAY vs VIG: Complete Analysis 2026

CBAYStock

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Full CBAY Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this CBAY vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBAY vs SCHDCBAY vs JEPICBAY vs OCBAY vs KOCBAY vs MAINCBAY vs DGROCBAY vs NOBLCBAY vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.